Phylos' cytokine microarrays gains US grant:
This article was originally published in Clinica
Executive Summary
Biopharmaceutical firm Phylos has gained a grant from the US National Institute of Allergy and Infectious Disease (NIAID) to develop protein microarrays using the firm's Trinectin binding proteins as capture and detection agents. The multiplex array is a high-throughput product that measures cytokines in small volumes of biological samples. The grant, the second from the NIAID, will fund the project over the next two years, says the Lexington, Massachusetts firm.